LCL161 in MF. (A) Swimmer plot for all responding patients. The legend embedded in the graph indicates the markers of CI and other responses. Disease stages per IPSS: Int 2, intermediate-risk 2; high, high-risk MF. (B) Table of characteristics and responses. All responses are per IWG-MRT 2013 response criteria for MF. TSS, total symptom score; Hgb, hemoglobin (g/dL); spln, spleen; CR (cyto), complete remission cytogenetics. Prior RX: Ara, Aransep; Thal, thalidomide; RUX, ruxolitinib; Pomalid, pomalidomide; DAC, decitabine; IA, idarubicin+ARA-C; alloSCT, allogeneic stem cell transplant; ACE-011, sotatercept. IFN, interferon; PEG IFN, pegylated interferon; Revlimid, lenalidomide; ANAG, anagrelide; AZA, azacytidine. WBC, white blood cell count (×10³/μL); PLT, platelet (×10³/μL); RespDUR (m), response duration in months, TxDUR (m), treatment duration in months (C) Spleen changed in size shown by waterfall plot. Each bar represents an individual patient response. All spleen size measurements in this study were performed by physical examination (palpation). Bsln, baseline spleen size. (D) LCL161 in MF anemia responders (n = 6). All responses are per IWG-MRT 2013 criteria for MF.